Janux Therapeutics, Inc.
JANX
$25.32
-$1.67-6.19%
| Weiss Ratings | JANX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | JANX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | JANX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.80 | |||
| Price History | JANX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -15.94% | |||
| 30-Day Total Return | -29.69% | |||
| 60-Day Total Return | -56.20% | |||
| 90-Day Total Return | -45.55% | |||
| Year to Date Total Return | -52.44% | |||
| 1-Year Total Return | -28.47% | |||
| 2-Year Total Return | 117.15% | |||
| 3-Year Total Return | 61.79% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -62.36% | |||
| 52-Week Low % Change | 4.73% | |||
| Price | JANX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $71.71 | |||
| 52-Week Low Price | $25.77 | |||
| 52-Week Low Price (Date) | Apr 03, 2025 | |||
| 52-Week High Price (Date) | Dec 05, 2024 | |||
| Valuation | JANX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.60B | |||
| Enterprise Value | 593.10M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.28 | |||
| Earnings Per Share Growth | -4.61% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 144.87 | |||
| Price/Book (Q) | 1.56 | |||
| Enterprise Value/Revenue (TTM) | 56.02 | |||
| Price | $25.32 | |||
| Enterprise Value/EBITDA (TTM) | -6.13 | |||
| Enterprise Value/EBIT | -6.00 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | JANX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 56.83M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | JANX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 751 4493 | |||
| Address | 10955 Vista Sorrento Parkway San Diego, CA 92130 | |||
| Website | www.januxrx.com | |||
| Country | United States | |||
| Year Founded | 2017 | |||
| Profitability | JANX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -933.57% | |||
| Profit Margin | -651.62% | |||
| Management Effectiveness | JANX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -8.57% | |||
| Return on Equity | -- | |||
| Income Statement | JANX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 10.59M | |||
| Total Revenue (TTM) | 10.59M | |||
| Revenue Per Share | $0.19 | |||
| Gross Profit (TTM) | -57.80M | |||
| EBITDA (TTM) | -96.79M | |||
| EBIT (TTM) | -98.85M | |||
| Net Income (TTM) | -68.99M | |||
| Net Income Avl. to Common (TTM) | -68.99M | |||
| Total Revenue Growth (Q YOY) | -100.00% | |||
| Earnings Growth (Q YOY) | -71.93% | |||
| EPS Diluted (TTM) | -1.28 | |||
| EPS Diluted Growth (Q YOY) | -41.21% | |||
| Balance Sheet | JANX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.03B | |||
| Cash Per Share (Q) | $18.04 | |||
| Total Current Assets (Q) | 1.03B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.02B | |||
| Current Ratio (Q) | 59.205 | |||
| Book Value Per Share (Q) | $17.32 | |||
| Total Assets (Q) | 1.06B | |||
| Total Current Liabilities (Q) | 17.46M | |||
| Total Debt (Q) | 23.03M | |||
| Total Liabilities (Q) | 38.74M | |||
| Total Common Equity (Q) | 1.02B | |||
| Cash Flow | JANX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -258.02M | |||
| Cash from Financing (TTM) | 713.24M | |||
| Net Change in Cash (TTM) | 411.40M | |||
| Levered Free Cash Flow (TTM) | -26.14M | |||
| Cash from Operations (TTM) | -43.81M | |||
